With the election over, no matter where your politics lie, it’s a huge relief for biotech investors scared off by the tough rhetoric from the Democratic Party towards big Pharma. With the potential of stiffer regulations, the sector experienced a bit of a nose dive.
Now that Republicans control the White House, Senate and Congress, biotech investors can breathe a sigh of relief and new investors can confidently jump back in. Several companies in the sector trading at a discount present a few opportunities warranting your immediate attention.
Endonovo Therapeutics, Inc. (ENDV), a developer of bioelectronic devices and non-invasive electroceuticals for the treatment of inflammatory conditions in vital organs, is trading at just above 9 cents which is down 89% from its 52 week high from last spring. If Endonovo can make its way back to the highs it was near prior to the campaign, that would represent an almost 900% gain.
But why would this happen?
Recently, ENDV announced the expansion of its liver disease research program and its Cytotronics™ platform to create a high-fidelity drug development and toxicology testing platform. The goal is to lower drug development costs while increasing the safety and effectiveness of drugs by allowing certain diseases to be modeled in the lab.
With money coming back into the sector, testing and trials are expected to increase.
This news means ENDV could be a huge beneficiary from this activity. “Right now a Phase I trial can cost roughly $15 million and take several years to complete,” stated Endonovo CEO, Alan Collier. “Topping that off, only 10 percent of drugs entering Phase I trials actually make it to market translating into large financial losses for the pharmaceutical industry.”
“This problem is not isolated to early clinical trials; numerous drugs have been withdrawn from the market with over 40 percent of marketing candidate drugs being terminated as a result of unexpected toxic effects, particularly in the liver.”
Mr. Collier continued, “The inability to test drugs early on in the drug development process for their potential toxic effects coupled with the ineffectiveness of animal models mimicking human drug toxicity remains a huge bottleneck for the pharmaceutical industry in a time where development costs of a new drug exceeds $2.5 billion.”
The global in-vitro toxicology testing market was valued at $20.2 billion in 2014 with forecasts projecting it reaching a value of $44.7 billion by 2020, growing at an estimated CAGR of 10.5% from 2015 to 2022, according to Grand View Research. The increase in demand for in-vitro toxicology testing is attributable to novel and promising technologies in analytical laboratories, such as organ-on-a-chip technologies and bioinformatics.
About ENDV’s Cytotronics Platform
Endonovo’s Cytotronics™ platform uses bioelectronics to control and enhance cell functions, allowing 3D intelligent cell cultures to be implemented in growing and enhancing stem cells and tissues for the development of cell therapies, disease modeling, ADME (absorption, distribution, metabolism, and excretion) and toxicology testing. The Company’s Cytotronics™ platform, which uses Time Varying Electromagnetic Field (TVEMF) technology, has already demonstrated great promise in growing and maintaining cells and tissues for 180 days in culture, as well as producing growth factors and cytokines. Endonovo’s technology was able to expand blood forming stem cells (CD34+38- cells) over 80 fold and expand human mesenchymal stem cells over 100 fold in as few as 6 days.
Corbus Technologies shot up in price recently after announcing positive stage 2 clinical trial results for Resunab in treating diffuse cutaneous systemic sclerosis was safe and exceeded company expectations.
Abeona Therapeutics recently began receiving quite a bit of attention after releasing positive Third Quarter results after a 2 week stretch which saw the company announcing closing of its $42 million underwritten offering of common stock and receiving Fast Track designation from the FDA for ABO-102.
Shares of Celldex Therapuetics (CLDX) were up Monday after the biotech presented data on CDX-1140 at the Society for Immunotherapy of Cancer (SITC) annual meeting on Saturday.
The preclinical data presented at SITC showed that the drug could bind to its target, CD40, turning on the receptor that activates the immune system, which can then attack a tumor. Celldex is completing the preclinical development for CDX-1140, with plans to start clinical development next year. The ultimate plan is to test CDX-1140 in combination with other immunotherapies or conventional cancer treatments.
Ocular Therapeutix Inc. (OCUL) shares surged Monday after the company said its eye treatment had positive topline results in a late-stage clinical trial. The company said Dextenza, an insert intended to treat eye inflammation and pain after surgery, met primary efficacy endpoints for both. Dextenza failed to get Food and Drug Administration approval in late July, but Ocular said it planned to resubmit its application with the agency by the end of the year and would file for a post-surgical eye pain indication if approved.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Click Here.
Media Contact
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspecualtors.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/disclaimer/